Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belapectin - Galectin Therapeutics

Next Previous
Drug Profile

Belapectin - Galectin Therapeutics

Alternative Names: Galactoarabino-rhamnogalaturonate; GR MD 02

Latest Information Update: 27 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Galectin Therapeutics
  • Developer Galectin Therapeutics; Providence Cancer Center; Providence Health & Services
  • Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antipsoriatics; Carbohydrates; Hepatoprotectants; Polysaccharides; Skin disorder therapies; Small molecules
  • Mechanism of Action Galectin 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Head and neck cancer; Lung cancer; Malignant melanoma; Orofacial cancer

Highest Development Phases

  • Phase II/III Liver cirrhosis
  • Phase II Atopic dermatitis; Hepatic fibrosis; Plaque psoriasis
  • Phase I Head and neck cancer; Lung cancer; Malignant melanoma
  • Preclinical Arrhythmias; Pulmonary arterial hypertension; Pulmonary fibrosis
  • No development reported Breast cancer; Diabetic nephropathies; Fibrosis; Orofacial cancer; Prostate cancer; Renal fibrosis
  • Discontinued Non-alcoholic steatohepatitis

Most Recent Events

  • 11 Oct 2023 Adverse events and pharmacokinetics data from a phase IIb/III trial in Liver cirrhosis presented at the The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases Session (AASLD-2023)
  • 11 Oct 2023 Adverse events data from a phase I trial in Hepatic impairment presented at the The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases Session (AASLD-2023)
  • 11 Oct 2023 Efficacy data from a phase II trial in Hepatic fibrosis and Liver cirrhosis presented at the The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases Session (AASLD-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top